Aditxt, Inc. (NASDAQ:ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. (“Adimune™) and its plans towards submission of a Clinical Trial Application (“CTA”) for its immunotherapeutic technology drug candidate, ADI™-100 (“ADI™-100” or “ADI™”). The CTA application will request approval for Adimune™ to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023. A second study is also planned for type 1 diabetes.
Amgen Touts Early Lumakras Combo Data In KRAS Cancer Settings
BMO Capital Markets says that while Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) + PD1i data was delayed to the August 7 presentation, it did get data on the Lumakras + SHP2 inhibitor combination.
